Immunological studies of HTLV-I associated myelopathy. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Immunological studies of HTLV-I associated myelopathy.

Autoimmunity. 1988;1(2):125-31. Unique Identifier : AIDSLINE MED/92089470
Kitajima I; Osame M; Izumo S; Igata A; Third Department of Internal Medicine, Faculty of Medicine,; Kagoshima University, Japan.

Abstract: We report the immunological studies of 50 cases with a chronic progressive myelopathy associated with elevated antibodies to human T-cell lymphotropic virus type I (HTLV-I) and adult T-cell leukemia-like cells (HAM). These are as follows: (1) T-cell activation; (2) increase of the OKT4/OKT8 ratio, due mostly to increased inducer/helper T cells and/or decreased suppressor/cytotoxic T cells; (3) decrease of natural killer cell numbers and activity; and (4) increase of immunoglobulins (IgG, IgA). Our results provide evidence that autoimmune events may participate in the pathogenesis of HAM and may be relevant in the hypothesis of common immune mechanisms between HAM and HTLV-I positive tropical spastic paraparesis.
Keywords: Adult Aged Comparative Study Complement/ANALYSIS Female Human HTLV-I Antibodies/*ANALYSIS Immunoglobulins/ANALYSIS Killer Cells, Natural/IMMUNOLOGY Leukemia, T-Cell/IMMUNOLOGY Lymphocyte Subsets/IMMUNOLOGY Lymphocyte Transformation Male Middle Age Spinal Cord Diseases/*IMMUNOLOGY JOURNAL ARTICLEKWDadultagedcomparativestudycomplement/analysisfemalehumanhtlv-iantibodies/KWDanalysisimmunoglobulins/analysiskillercells,natural/immunologyleukemia,t-cell/immunologylymphocytesubsets/immunologylymphocytetransformationmalemiddleagespinalcorddiseases/KWDimmunologyjournalarticle
920430
M9240931

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .